PPG Industries
PPG INDUSTRIES INC
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$15.9B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
35.9%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-1.4%
Capital efficiency
★★★★☆position among all companies
19.8%
Revenue and profit
Performance, financial position and capital allocation
PPG Industries
Recent performance trends
PPG Industries
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$16.8 billion | US$15.6 billion | US$16.2 billion | US$15.8 billion | US$15.9 billion |
| Operating income | US$2.2 billion | US$2.0 billion | US$2.7 billion | Could not be retrieved | Could not be retrieved |
| Net income | US$1.4 billion | US$1.0 billion | US$1.3 billion | US$1.1 billion | US$1.6 billion |
| Total assets | US$21.4 billion | US$20.7 billion | US$21.6 billion | US$19.4 billion | US$22.1 billion |
| Shareholders' equity | US$6.3 billion | US$6.6 billion | US$7.8 billion | US$6.8 billion | US$7.9 billion |
| Net cash provided by (used in) operating activities | US$1.6 billion | US$1.0 billion | US$2.4 billion | US$1.4 billion | US$1.9 billion |
| Net cash provided by (used in) investing activities | US$-2.4 billion | US$-0.5 billion | US$-0.6 billion | US$0.1 billion | US$-0.7 billion |
| Net cash provided by (used in) financing activities | US$93.00 million | US$-0.4 billion | US$-1.6 billion | US$-1.4 billion | US$-0.5 billion |
| Cash and cash equivalents | US$1.0 billion | US$1.1 billion | US$1.5 billion | US$1.3 billion | US$2.2 billion |
Revenue scale in the same industry
PPG Industries
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 10 companies
- 14 Teva Pharmaceutical Industries LimitedFY Dec 2025 US$17.3B
- 15 EcolabFY Dec 2025 US$16.1B
- 16 PPG IndustriesThis companyFY Dec 2025 US$15.9B
- 17 KenvueFY Dec 2025 US$15.1B
- 18 THE Estee Lauder CompaniesFY Jun 2026 US$15.0B
- … 38 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.8 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$2.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.7 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$1.9 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.5 billion | Consolidated | Disclosed |
| Dividends paid | US$0.6 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$8.1 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0.2 billion | Consolidated | Disclosed |
| Net assets | US$7.9 billion | Consolidated | Disclosed |
| Net sales | US$15.9 billion | Consolidated | Disclosed |
| Net income | US$1.6 billion | Consolidated | Disclosed |
| Total assets | US$22.1 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.8 billion | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 35.9% | Consolidated | Calculated |
| Net margin | 9.9% | Consolidated | Calculated |
| Return on equity | 19.8% | Consolidated | Calculated |